Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Transmeta Corporation (TMTA)

5.364 Posts
Pagina: «« 1 ... 251 252 253 254 255 ... 269 »» | Laatste | Omlaag ↓
  1. [verwijderd] 9 februari 2006 15:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Helft bij opening op 1.34 er uitgedaan, De rest had ik op 1.20 dus die hou ik wel aan. Op de lange termijn zie ik het toch nog wel positief in.
  2. Ortega 9 februari 2006 15:41

    • Ortega

      Lid sinds: 03 feb 2004

      Laatste bezoek: 04 mrt 2025

    • Aanbevelingen

      Ontvangen: 392

      Gegeven: 1122

    •    Aantal posts: 2.437

    Tim ik hetzelfde. Ook op 1,34 wat eruit. Kan netzo goed weer naar 1,15 en dan kun je helemaal niks.
  4. [verwijderd] 9 februari 2006 17:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Pump_up_the_Volume_ schreef:

    Dit bericht lijkt me wat belangrijker

    Transmeta and Culturecom Mutually Terminate Contingent Processor Technology License and Sale Agreement for the Chinese Market
    Thursday February 9, 7:30 am ET

    SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 9, 2006--Transmeta Corporation (NASDAQ:TMTA - News), the leader in efficient computing technologies, announced today that it has mutually agreed with Culture.com Technology Limited (Culturecom) to terminate two related asset purchase and license agreements with Culturecom. Under those agreements, which the parties announced in May 2005, Transmeta would have sold its Crusoe(TM) product line to Culturecom and would have licensed Transmeta's 130-nanometer Efficeon(TM) technology to Culturecom to make and sell Efficeon-based products in China. The two companies mutually and amicably elected to terminate those agreements at this time based upon their mutual concern that they could not satisfy all of the approval conditions necessary to close the agreements in a timely fashion.
    belangrijkst voor mij waren indertijd andere deals..
    maar lager zal ie zeker gaan...
    hopelijk laag genoeg voor nieuws koopmoments

    als je lt zit..lastig, ik denk niet dat ie als een speer omlaag gaat nml
  5. [verwijderd] 9 februari 2006 18:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Contacts:
    Greg Rose
    Transmeta Corporation
    (408) 919-3000
    Investors: Michael Polyviou/Peter Schmidt
    Financial Dynamics
    (212) 850-5600
    Media: Lauren Stein
    (212) 850-5650
    TRANSMETA AND CULTURECOM MUTUALLY TERMINATE
    CONTINGENT PROCESSOR TECHNOLOGY LICENSE AND SALE AGREEMENT
    FOR THE CHINESE MARKET
    SANTA CLARA, CA. – February 9, 2006 – Transmeta Corporation (NASDAQ: TMTA), the
    leader in efficient computing technologies, announced today that it has mutually agreed with
    Culture.com Technology Limited (Culturecom) to terminate two related asset purchase and
    license agreements with Culturecom. Under those agreements, which the parties announced in
    May 2005, Transmeta would have sold its Crusoe™ product line to Culturecom and would have
    licensed Transmeta's 130-nanometer Efficeon™ technology to Culturecom to make and sell
    Efficeon-based products in China. The two companies mutually and amicably elected to
    terminate those agreements at this time based upon their mutual concern that they could not
    satisfy all of the approval conditions necessary to close the agreements in a timely fashion.
    “Our Crusoe and 130nm Efficeon processors are still considered very advanced, controlled
    technology from an export control perspective, even though they have reached the end of their
    competitive life-cycle for Transmeta’s ongoing business,” commented Arthur L. Swift, president
    and CEO of Transmeta. “After several meetings with U.S. government officials, Transmeta and
    Culturecom mutually concluded that the necessary technology export control approvals could
    not be obtained for these two agreements within the timeframe necessary to satisfy
    Culturecom’s commercial requirements.”
    The termination of the two agreements is not expected to have any adverse impact on
    Transmeta’s financial outlook. Transmeta has not included any potential benefit from any
    prospective transaction with Culturecom in its financial guidance or projections to date, in part
    because of the uncertainties associated with closing conditions such as technology export
    license approval for advanced microprocessor technologies.
    Transmeta and Culturecom have had a historical business relationship dating from 2003, when
    an affiliate of Culture.com, Chinese 2 Linux (Holdings) Limited, licensed Transmeta’s Midori
    Linux software for the development of embedded applications. Transmeta and Culturecom
    have reaffirmed their continuing commitment to work together on initiatives of mutual interest.
    About Transmeta Corporation
    Transmeta Corporation develops and licenses innovative computing, microprocessor and
    semiconductor technologies and related intellectual property. Founded in 1995, Transmeta first
    became known for designing, developing and selling its highly efficient x86-compatible softwarebased
    microprocessors, which deliver a balance of low power consumption, high performance,
    low cost and small size suited for diverse computing platforms. We also develop advanced
    power management technologies for controlling leakage and increasing power efficiency in
    semiconductor and computing devices. To learn more about Transmeta, visit
    www.transmeta.com.

    Safe Harbor Statement
    This release contains forward-looking statements made pursuant to the safe harbor provisions
    of the Private Securities Litigation Reform Act of 1995. Such statements speak only as of the
    date of this release, and Transmeta will not necessarily provide updates of our projections or
    other forward-looking statements. Investors are cautioned that such forward-looking statements
    are subject to many risks and uncertainties, and may differ materially or adversely from
    Transmeta’s actual results or future events. Important risk factors that could have material or
    adverse effects on Transmeta’s results include the ability for Transmeta to reach agreement
    with Culturecom on commercial initiatives and other risk factors. Transmeta urges investors to
    review Transmeta’s filings with the Securities and Exchange Commission, including its most
    recent reports on Forms 10-K, 10-K/A, 10-Q and 8-K, which describe these and other important
    risk factors that could have an adverse effect on its results. Transmeta undertakes no obligation
    to revise or update publicly any forward-looking statement for any reason.
    Transmeta is a trademark of Transmeta Corporation. All other product or service names
    mentioned herein are the trademarks of their respective owners.

  6. [verwijderd] 9 februari 2006 18:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The termination of the two agreements is not expected to have any adverse impact on
    Transmeta’s financial outlook. Transmeta has not included any potential benefit from any
    prospective transaction with Culturecom in its financial guidance or projections to date, in part
    because of the uncertainties associated with closing conditions such as technology export
    license approval for advanced microprocessor technologies
  8. [verwijderd] 16 februari 2006 21:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Na een stukje naar beneden te zijn afgegleden(slechte cijfers), nu een sprint omhoog.
    Geen idee waarom, op yahoo forums nog niet echt nieuws kunnen ontdekken, behalve dit:
    finance.messages.yahoo.com/bbs?.mm=FN...
    Maakt dat nu echt zo veel verschil, een of andere analist die denkt dat het goed gaat met bepaald aandeel?
    Denk dat ik ook maar analist wordt dan.
    Eerst ff aandelen kopen, dan zegen dat het daar goed mee gaat en weer verkopen altijd winst.

    Ik ook 1.4 gezien ;)
  9. Ortega 16 februari 2006 23:48

    • Ortega

      Lid sinds: 03 feb 2004

      Laatste bezoek: 04 mrt 2025

    • Aanbevelingen

      Ontvangen: 392

      Gegeven: 1122

    •    Aantal posts: 2.437

    Ja ik zit er nog steeds in. Wel iets afgebouwd.
    Ben erg benieuwd of dit morgen gaat doorzetten.
  10. gustaaf1e 17 februari 2006 00:34

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 04 mrt 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Stijging zal wel te verklaren zijn uit aankomende Q4-cijfers op 23/2. Mede gezien de outlook/verwachting aangegeven bij Q3-cijfers.
    Heb ook nog deel in porto.
    G
  12. [verwijderd] 17 februari 2006 01:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik had de helft verkocht en voor de overige een stoploss op 1.22 geplaatst.
    Heeft even gespand of ze waren ook afgegaan.
    Hopelijk komt er nu beterschap.
  17. [verwijderd] 22 februari 2006 19:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    zit er nu niet in

    morgenavond cijfers..

    iemand mening over huidige prijsniveau
    culturecom deal cancelled...nog ander betere outlook te verwachten?

    heb zelf laatste tijd niet vele nieuws over tmta of de cell chip gezien
  18. [verwijderd] 22 februari 2006 19:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    JaySS schreef:

    [quote=arak]
    kan je link niet openen, weet jij waar dei 10% van gisteren vandaan kwamen, in het laatste uur zeker. Maar waarom?

    bvd

    arak
    [/quote]

    finance.messages.yahoo.com/bbs?.mm=FN...

    Jay
    yahoo msges laden vandaag niet voor mij...kan iemand inhoud van dat bericht copy/paste doen hier?
  20. [verwijderd] 22 februari 2006 20:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    iemand?
    Re: SMART TIME TO BUY. NEXT STOP $5
    by: pitbull_trader2005
    Long-Term Sentiment: Strong Buy 02/16/06 02:29 pm
    Msg: 58707 of 59704

    I think Critical Path is planning a device with Xybernaut using the Transmeta chip that will revolutionize mobile computing.

    Transmeta's Chips Now a Fashion Statement
    By Michael Singer

    From desktop, to laptop, to your palm device, computers are getting smaller and more personal. Now, more companies are looking to make the computer part of your wardrobe.

    Pushing the technology forward is wearable/mobile computer maker Xybernaut (Quote, Chart), whose exploits to make wireless wearable and chic have been well documented. Now, the Fairfax, Va.-based company has signed on low-power chipmaker Transmeta (Quote, Chart) as part of its big picture plans to adorn people in computers. The companies said the goal of their collaboration is to "develop mobile and wearable computing technologies that meet the needs of a wide variety of industry sectors and end-user communities."



    Posted as a reply to: Msg 58673 by supertradeaxis
5.364 Posts
Pagina: «« 1 ... 251 252 253 254 255 ... 269 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.076
AB InBev 2 5.522
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.756
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.755
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 919
Aegon 3.258 322.905
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.342
Air France - KLM 1.025 35.089
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.943
Allfunds Group 4 1.503
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.823
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.410
AMG 971 133.779
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.786
Arcelor Mittal 2.034 320.776
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.337
ASML 1.766 108.280
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 515
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404